New EU Portal To Track Pricing & Reimbursement Applications
Move Will Help Uncover Root Causes Of Medicines Unavailability & Patient Access Delays
To improve patient access to approved drugs, European R&D-based companies have pledged to apply for pricing and reimbursement of drugs in all EU member states within two years of product approval. A new portal set up by EFPIA will track the progress of these applications, documenting reasons for pricing delays and barriers.
You may also be interested in...
Legal and industry expert Alexander Natz sets out key questions and answers to help companies prepare for new EU regulations on health technology assessments, one of the biggest developments to affect the pharmaceutical industry in over a decade.
Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.
Consultancy firms must have at least five years of experience in carrying out independent GMP or GDP audits if they want to apply to become a “compliance monitor” under a new MHRA scheme to keep track of drug companies that fail to comply with GMP/GDP requirements.